ALGS · Aligos Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Aligos Therapeutics Inc Is A Clinical-Stage Biotechnology Company Focused On Developing Therapeutics For Liver Diseases And Viral Infections. Its Pipeline Includes Drug Candidates Targeting Chronic Hepatitis B Virus (Hbv) Infection, Metabolic Dysfunction-Associated Steatohepatitis (Mash), Obesity, And Coronavirus Infections, With Programs Such As Pefivfoscorvir Sodium For Hbv, Alg-055009 For Mash And Obesity, And Alg-097558 For Coronavirus Infections.

HealthcareNasdaqUSVery Low Float

$8.60

+46.0% latest move

Price & move as of the most recent catalyst (Jul 6) — not a live quote.

FLOAT

4.8M

FREE FLOAT %

77%

SHARES O/S

6.2M

MARKET CAP

$34.5M

EXCHANGE

Nasdaq

COUNTRY

ALGS Catalyst History

Corporate DealsUpfront Payment DealJul 6, 2026 · 4:05pm ET

ALGSAligos Therapeutics, Inc.

Aligos Therapeutics Enters Exclusive License Deal for Pevifoscorvir Sodium in Greater China

Received an upfront payment of $25 million.

Be early on the next ALGS spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →